A randomized, controlled pivotal Phase 3 clinical trial comparing the combination of oral rigosertib plus azacitidine to azacitidine plus placebo in high risk myelodysplastic syndrome patients.
Phase of Trial: Phase III
Latest Information Update: 27 Mar 2017
At a glance
- Drugs Rigosertib (Primary) ; Azacitidine
- Indications Myelodysplastic syndromes
- Focus Registrational; Therapeutic Use
- Sponsors Onconova Therapeutics
- 27 Mar 2017 The protocol for this trial is expected to be ready for submission to the EMA and the FDA for a Special Protocol Assessment during the second or third quarter of 2017, according to an Onconova Therapeutics media release.
- 07 Oct 2016 New trial record